The GLP-1 insurance denial study, a poster presented at ObesityWeek on November 15, 2026, found that about one in three first requests was denied, even though patients met clinical treatment criteria. About half of denials involved plan exclusions or coverage limits. That is a broader category than a plan refusing to cover weight-loss medicines altogether.

Prior authorization is the insurer's review before it agrees to pay. GLP-1 medicines act on a gut-hormone signal involved in appetite and blood sugar. A doctor's prescription and an insurer's payment decision answer different questions.

GLP-1 insurance denial study: what happened

As of November 19, 2026, the day this article was written, a new conference abstract describes that gap. The ObesityWeek schedule lists poster 531 for November 15. Ro announced the research on November 14.

Researchers looked back at records from 225,000 randomly selected adults aged 18–63 using Ro, a telehealth company. All had commercial insurance, meaning private coverage, and met the study's clinical criteria for weight-management treatment.

The benefits checks concerned semaglutide and tirzepatide. They took place from January through September 2025. Authorization outcomes were observed through October 30, 2025. Among 69,462 people with initial treatment authorization submissions:

Initial result Share
Approved 53.2%
Denied 35.7%
Unknown 11.2%

The published percentages are rounded. The denial figure applies to the submission group, not all 225,000 people.

Among denials, the leading reasons were:

Recorded reason Share of denials
Plan exclusion or coverage limitation 51.1%
Clinical eligibility requirements not met 24.7%
Previous-treatment or other therapy requirements not met 12.7%

The first category combines two reasons. It cannot tell us how many denials were blanket exclusions alone. Meeting the study's clinical criteria also did not guarantee meeting a particular insurer's rules.

This is a conference abstract, a brief research summary. It is not a peer-reviewed journal paper checked by independent experts. The authors include researchers from Ro and from Amgen, a drugmaker, alongside other collaborators. Both companies have an interest in treatment access.

What a plan exclusion means for a denied request

A benefit exclusion means the plan does not cover a particular treatment or use. A medical-necessity denial means the plan judged the submitted medical case against its coverage rules and said it did not qualify.

Those require different conversations. More medical records can address a disputed clinical requirement. They do not automatically add an excluded benefit.

HealthCare.gov explains that internal appeals can challenge denials, including decisions involving excluded benefits or medical necessity. An exclusion does not mean there is nothing to question: the wrong rule may have been applied.

But changing the benefit itself is different from challenging a decision. The Department of Labor identifies choosing and changing an employer's benefit package as employer decisions. The benefits team can explain whether an exception request exists and who decides broader coverage changes.

Our guide to a denied GLP-1 prior authorization covers the documents and appeal process. The immediate question is which written reason applies.

Why a covered-drug list is only part of the answer

A formulary is the plan's list of covered medicines. Being listed can still come with a required review before payment.

A 2025 JAMA Network Open study examined Medicare Part D, Medicare's prescription-drug benefit. It studied semaglutide under the Ozempic and Rybelsus names, plus tirzepatide under Mounjaro. By the third quarter of 2024, reported prior authorization rates exceeded 80% for each medicine among covering plans.

That is historical Medicare evidence, not a prediction for today's commercial plans. It shows why “covered” and “no authorization needed” are different answers.

Semaglutide and tirzepatide also had separate benefits checks in the new Ro abstract. Coverage without prior authorization was uncommon for both. The abstract does not establish which medicine would be easier for one reader to obtain.

What the study cannot tell us

These are one company's patients, not a national sample of everyone seeking treatment. Medicare patients and people without insurance were outside the study. So were people covered by Medicaid, the state and federal health program. Records from 2025 cannot establish the denial rate in late 2026.

The abstract reports initial decisions, not what happened after appeals or resubmissions. Unknown outcomes cannot be counted as either approvals or denials. It also does not establish why one insurer behaved differently from another.

As of November 19, 2026, the day this article was written, an October 15, 2026 paper in Health Affairs Scholar offers another reason to compare rates carefully. Across 2018–2024, it found 7.9% of people had their first recorded GLP-1 pharmacy claim denied. A pharmacy claim is a request for payment processed through insurance at the pharmacy.

That study included different medicines and insurance groups. It measured pharmacy claims, while Ro measured treatment-start authorization submissions. The percentages answer different questions; neither establishes the odds for your own request.

What these findings say about a prescription

An insurance denial does not establish which medication suits someone. These findings also do not show that a compounded prescription is interchangeable with the branded products studied.

Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. As of November 19, 2026, the day this article was written, the U.S. Food and Drug Administration explains this distinction.

A licensed provider may still prescribe — that decision is between you and your doctor.

What to watch next

A fuller report could separate outright exclusions from other coverage limits. Follow-up could show how many people eventually received treatment, how long it took, and whether appeals changed the outcome.

For someone already prescribed treatment, today's denial and next year's benefits are separate concerns. Our guides to insurance dropping GLP-1 coverage and open enrollment GLP-1 coverage cover those changes.

Payment can remain a problem after approval. The GLP-1 cost and adherence study addresses the separate question of keeping treatment affordable over time.

The useful distinction remains simple: a prescribing decision, a covered benefit, and an accepted payment request are three separate things.

At Promise, a licensed U.S. provider reviews every request and may prescribe or decline; not everyone qualifies.